FindTrial
Sign In

Therapeutic Window Study of Vancomycin in Cerebrospinal Fluid: Efficacy and Safety Analysis for Central Nervous System Infections

Therapeutic Window Study of Vancomycin in Cerebrospinal Fluid: Efficacy and Safety Analysis for Central Nervous System Infections

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500113096
Enrollment
Unknown
Registered
2025-11-25
Start date
2025-11-25
Completion date
Unknown
Last updated
2025-12-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Central nervous system infection

Interventions

Vancomycin treatment observation group:None

Sponsors

Shanghai General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Age >= 18 years; 2.Confirmed diagnosis of central nervous system infection (such as bacterial meningitis, ventriculitis); 3.Undergoing treatment with vancomycin; 4.The patient or their family member signs the informed consent form;

Exclusion criteria

Exclusion criteria: 1.Allergy to vancomycin; 2.Concurrent severe illnesses (such as advanced cancer, severe hepatic or renal insufficiency); 3.Pregnant or breastfeeding women; 4.Unable to cooperate with the completion of the research follow-up;

Design outcomes

Primary

MeasureTime frame
Clinical cure rate;—

Secondary

MeasureTime frame
Hospital stay;Mortality rate;Recurrence rate;Safety;Nephrotoxicity;—

Countries

China

Contacts

Public ContactMiao Wenqing

Shanghai General Hospital

miaowq0619@163.com+86 21 6324 0090

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026